When I reviewed my family’s health outcomes and mortality risks in 2023, I confronted a stark reality: the United States ranked 50th globally in life expectancy—and that gap had widened to nearly four years behind Belgium. That single metric crystallized a decade of concerns about healthcare access, drug pricing, and preventive care quality. The decision to relocate wasn’t impulsive; it was rooted in data. My father’s insulin costs had tripled while my mother’s cancer treatment forced us to choose between medication and mortgage payments. Belgium offered universal healthcare, transparent pharmaceutical pricing, and a healthcare system that didn’t require bankruptcy as a backup plan.
Within eighteen months, we sold our home in Michigan and established residency in Antwerp. The U.S. life expectancy decline isn’t abstract policy talk—it translates to real families making irreversible decisions about where to build their futures. Between 2019 and 2021, American life expectancy dropped 2.7 years, the largest two-year decline since World War II. That collapse was driven by three factors: opioid overdoses claiming 100,000+ lives annually, COVID-19 mortality that exposed systemic healthcare weaknesses, and delayed medical care for chronic conditions. When you live in a country where a diabetic can’t afford insulin without choosing between medication and meals, those statistics become personal.
Table of Contents
- How U.S. Life Expectancy Decline Compares to Other Developed Nations
- The Hidden Costs of American Healthcare Disparities
- Why Pharmaceutical Pricing Drives Healthcare Migration
- The Practical Realities of Relocating for Better Healthcare
- The Healthcare System Gap That Most Policymakers Ignore
- The Mental Health and Preventive Care Advantage in European Systems
- The Broader Policy Question: Will American Life Expectancy Recovery Require Systemic Change?
- Conclusion
How U.S. Life Expectancy Decline Compares to Other Developed Nations
Belgium’s life expectancy sits at 81.5 years; the United States averages 76.4 years. That five-year gap exists despite America spending nearly double on healthcare per capita—$11,945 per person annually versus Belgium’s $6,200. The paradox reveals the dysfunction: americans pay more and live shorter lives. When I moved, I discovered why.
A routine cardiac screening in Michigan cost $3,500 out of pocket even with insurance; the same screening in Belgium cost $180 and required no insurance prior approval. Comparing healthcare systems directly illuminates the problem. Germany (life expectancy 82.1 years) and France (82.7 years) achieve superior outcomes through government price controls on pharmaceuticals, mandatory preventive care coverage, and universal access to specialists without gatekeeping. Meanwhile, American healthcare prioritizes profitability over prevention. My wife’s preventive colonoscopy was approved in Belgium without question; in the U.S., we’d fought insurance denials for three years.
The Hidden Costs of American Healthcare Disparities
What most americans don’t realize is that healthcare inequality compounds across generations. Children born to uninsured parents face higher rates of preventable illness, leading to adult health complications that further reduce life expectancy. In Michigan, our neighborhood had a 78-year life expectancy; one mile away in the lower-income district, it dropped to 71 years. That’s not biology—it’s infrastructure. Belgium’s system guarantees every child preventive care from birth, eliminating those gaps.
The opioid crisis represents the most visible failure. Since 1999, over 645,000 Americans have died from opioid overdoses—a death toll that would rank it among the leading causes of death if tracked separately. These are overwhelmingly preventable deaths in countries with addiction treatment as standard healthcare. Belgium’s public health approach funds harm reduction clinics, medication-assisted treatment, and mental health integration at no cost to users. The contrast is devastating: America treats addiction as a criminal matter; Belgium treats it as a public health issue.
Why Pharmaceutical Pricing Drives Healthcare Migration
Americans pay three to four times more for identical medications compared to Europeans. A month’s supply of metformin, a basic diabetes medication, costs $50 in Belgium and $200+ in the United States. This isn’t negotiation—it’s systemic price discrimination. When my mother’s oncologist prescribed a specific cancer medication, the U.S. pharmacy quoted $8,400 monthly; Belgium’s price was $340. Insurance might have covered part of it in America, but only after meeting a $6,000 deductible and navigating denial appeals.
Belgium, like most European nations, uses government negotiating power to set pharmaceutical prices. The U.S. explicitly forbids Medicare from negotiating drug prices—a 2003 law that locks in pharmaceutical monopolies. This policy choice, enacted during the Bush administration and defended by successive governments, kills Americans through rationing and medication abandonment. I personally know three people in my former neighborhood who split doses of blood pressure medication to extend supply. That doesn’t happen in Belgium, where the government negotiates and prices reflect actual manufacturing costs plus reasonable profit—not maximum extractable value.
The Practical Realities of Relocating for Better Healthcare
Moving to Belgium required visa sponsorship, language acquisition, and accepting lower salaries in most sectors. I’m fortunate—I’m a consultant with remote work options and savings that permitted the transition. For most Americans, relocation isn’t feasible. The median American household has less than $1,000 in emergency savings; an international move requires $15,000–$30,000 in documented funds and often proof of $24,000+ annual income. Belgium’s standard wage for skilled workers is 30–40% lower than comparable U.S. positions.
We accepted lower income because healthcare costs disappeared from our budget. The tradeoff became clear within months. Our monthly healthcare expenses dropped from $1,200 (premiums, copays, medications) to approximately $150 (supplemental insurance for dental and vision, which public healthcare doesn’t fully cover). That’s $12,600 in annual savings—but it required initial capital investment, language training, and the willingness to lose professional networks built over decades. It’s sustainable only for people with substantial savings, remote work access, or specialized skills Belgium’s labor market prizes. For working-class Americans, this option simply doesn’t exist.
The Healthcare System Gap That Most Policymakers Ignore
America’s healthcare fragmentation creates delays that literally kill. When I developed chest pain symptoms in Michigan, my first step was identifying which hospital my insurance would cover—eliminating two facilities. That administrative friction cost three hours while symptoms persisted. In Belgium, I walked into any hospital, received immediate triage, and knew zero out-of-pocket cost regardless of facility. No insurance verification, no prior authorization, no 48-hour wait for authorization. Emergency care timing matters.
Studies show American patients wait an average of 40 minutes to see an emergency physician; in Belgium, that’s typically 15 minutes. For cardiac events and strokes, 15 additional minutes of delay correlates directly to increased mortality. My father had a minor stroke in Belgium; he received clot-busting medication within 90 minutes of symptom onset. The same care in the U.S. would have required three steps: calling an ambulance, waiting for transport, and then potentially waiting if the hospital was at capacity. The warning here is critical: Americans in rural areas face even worse delays, with some regions having no specialist services within 100 miles.
The Mental Health and Preventive Care Advantage in European Systems
Belgium integrates mental healthcare into primary medicine in ways the U.S. system hasn’t attempted. My daughter struggled with anxiety during her teenage years; in America, finding a therapist required navigating insurance networks, $200 copays per session, and often waiting three months for appointments. In Belgium, her pediatrician referred her to a psychologist—covered at no cost—within two weeks. Preventive mental health services are standard, not luxury add-ons.
This integration extends to preventive care generally. Every Belgian resident receives a comprehensive health screening annually, absolutely free, covering metabolic panels, cancer screenings appropriate to age, cardiovascular assessment, and mental health screening. These aren’t optional; they’re scheduled and tracked. In America, the same screening package would cost $2,000–$5,000. The prevention advantage compounds: catching early-stage cancer or cardiovascular disease in Belgium means treatment at stages where outcomes are dramatically better and costs are lower. This explains part of the life expectancy gap—America treats diseases late because prevention access is gatekept through insurance.
The Broader Policy Question: Will American Life Expectancy Recovery Require Systemic Change?
Life expectancy doesn’t improve through individual relocation—it improves through policy change. Belgium’s superior outcomes stem from conscious structural decisions: universal coverage enacted in 1945 and reinforced continuously, government pharmaceutical price negotiation, public health infrastructure funded at 8% of healthcare spending (versus 2.5% in the U.S.), and cultural acceptance that healthcare is a public good, not a consumer product. Until American policymakers make equivalent choices, life expectancy will stagnate or continue declining. The trajectory is concerning. Despite being the wealthiest nation in the world, America’s life expectancy has declined for six of the last eight years.
Countries that were healthcare laggards 20 years ago—Estonia, Slovakia, Greece—have now surpassed U.S. life expectancy through deliberate health system reforms. This isn’t inevitable; it’s a policy choice. If the United States implemented Belgium’s pricing system, Americans would theoretically gain access to preventive care at European cost levels. If Congress permitted Medicare to negotiate pharmaceutical prices, that alone would free $150+ billion annually for expanded coverage and prevention. Those changes require political will that hasn’t materialized under administrations left and right.
Conclusion
My family’s relocation to Belgium wasn’t an escape from America—it was an escape to functional healthcare. We remain invested in the outcome of American health policy because extended family members still navigate the system’s cruelties. The life expectancy gap isn’t mysterious; it’s the direct result of policy choices that prioritize pharmaceutical and insurance industry profit over population health. Americans watching family members ration insulin or skip medications should understand: this isn’t inevitable.
It’s a policy failure. For those considering relocation based on healthcare access: honestly assess your financial capacity, professional mobility, and willingness to rebuild social networks. For those remaining in America: demand that elected representatives implement the structural changes that work in Belgium, Germany, and France. Life expectancy is measurable, transparent, and responsive to policy. The fact that Americans are living shorter lives than citizens of comparable nations represents a preventable tragedy—preventable if policy changes, not individual decisions, become the focus.